Takeda's Response to COVID-19 If you were diagnosed with COVID-19 and have recovered, you may be able to help in furthering research into a potential therapy for others by donating your plasma.

Guided Search

Enter the condition you are interested in

Next

Find a Trial

Click for Guided SearchOpen Guided Search
Condition or Trial Identifier
Location

FILTERS

FILTERS

Clear all

FILTERS

Clear all
Medical Condition / Disease  
Drug / Treatment  
Trial Status  
Age

or Select Age Range:

Trial Type  
Phase  
Trial Identifier  
Results  
Show Results

Results

(33)
Selected Filters
Recruiting
All Ages

Hereditary Angioedema (HAE)

FIRAZYR General Drug Use-Results Survey (Japan)
6,176 miles (9,940 km) from
New Britain, Pennsylvania
All Ages
Recruiting
From 12 years

Hereditary Angioedema (HAE)

A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects with Hereditary Angioedema
6,262 miles (10,078 km) from
New Britain, Pennsylvania
From 12 years
Recruiting
All Ages

Hereditary Angioedema (HAE)

Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)
3,529 miles (5,679 km) from
New Britain, Pennsylvania
All Ages
Recruiting
All Ages

Hereditary Angioedema (HAE)

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)
3,242 miles (5,217 km) from
New Britain, Pennsylvania
All Ages
Recruiting
All Ages

Hereditary Angioedema (HAE)

Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)
62 miles (99 km) from
New Britain, Pennsylvania
All Ages
AVAILABLE
2 - 11 years

Hereditary Angioedema (HAE)

Expanded Access for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Participants Aged 2 to Less Than (<) 12 Years
62 miles (99 km) from
New Britain, Pennsylvania
2 - 11 years
Recruitment Complete
2 - 11 years

Hereditary Angioedema (HAE)

A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of Age
62 miles (99 km) from
New Britain, Pennsylvania
2 - 11 years
Completed
From 18 years

Hereditary Angioedema (HAE)

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
140 miles (225 km) from
New Britain, Pennsylvania
From 18 years
Completed
From 18 years

Hereditary Angioedema (HAE)

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
4,083 miles (6,571 km) from
New Britain, Pennsylvania
From 18 years
Completed
From 12 years

Hereditary Angioedema (HAE)

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
58 miles (94 km) from
New Britain, Pennsylvania
From 12 years